中 / EN



中文 EN

About Us

Home page

Introduction

History

Honors



Liaoning Cheng Da Biotechnology Co., Ltd. (CDBIO)

Dedicatedly Offer Top-tier Biological Products and Wholeheartedly Safeguarding the Life and Health of Humanity

Established in 2002, Liaoning Cheng Da Biotechnology Co., Ltd. has been on a remarkable journey with the corporate mission of Dedicatedly Offer Top-tier Biological Products and Wholeheartedly Safeguarding the Life and Health of Humanity, the core values of Integrity & Trustworthiness, Benevolence & Harmony, Responsibility & Collaboration, and the firmly corporate philosophy of Confronted Lives with Responsibility. CDBIO is striving to ascend to the ranks of outstanding international biopharmaceutical company.

Over 2000 Districts & County-level CDCs

Marketing Coverage

Over 30 Countries

International Business

16.8 Billion Yuan

Operating Revenue in 2023

3 Manufacturing Bases

Manufacturing Facilities

2 R&D Centers

R&D Facilities

Over 20 Kinds of Vaccine Product

Products under Pipeline

Currently, CDBIO's product portfolio available on the market encompasses Rabies Vaccine for Human Use (Vero Cell) (CPRV) and Inactivated Japanese Encephalitis Vaccine for Human Use (Vero Cell) (IJEV). The CPRV has achieved a remarkable milestone with over 500 million doses safely administered worldwide. As for the IJEV, it stands out for its extended scope of applicable populations along with an even higher standard of purity and safety ensuring utmost reliability and peace of mind for users.

The company has established R & D centers in Shenyang, Beijing, and Benxi, having a R&D team of over 200 members, whose pipeline of products under development encompasses a diverse array of innovative vaccine products including Recombinant Human Papillomavirus 15-valent Vaccine (Escherichia coli) (HPV 15), Serogroup B Meningococcal Outer Membrane Vesicle Vaccine (Men B), 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV 20), and Recombinant Zoster Vaccine, etc.

Backed by a professional promotion team, CDBIO’s marketing network has reached over 2,000 districts & county-level CDCs across China. Simultaneously, CDBIO provides product services to customers from more than 30 countries worldwide with the gained significant brand recognition and a high reputation of vaccine products.

On October 28, 2021, Chengda Bio was successfully listed on the SSE Cotron Board (stock code 688739). The company established Shenzhen Chengda Biological Investment Co., Ltd. in CVC Innovation Service Park, Futian District, Shenzhen, as a foreign investment platform for Chengda Biological, mainly through investment, incubation, mergers and acquisitions and business development in the biomedical and medical health industry chain, to achieve the industrial linkage and coordinated development of parent and subsidiary companies.

In July 2022, the company invested in the construction of a biotechnology product R & D and production base in Shenyang Hunnan Biomedical Industrial Park, covering an area of about 172 acres and a total construction area of about 180000 square meters. The project construction period is 48 months. The production base will be mainly used for the industrialization of the company's innovative vaccine varieties. The construction of the new base will accelerate the industrialization process of the company's products under research, further expand the company's production and operation space, and lay the foundation for the company to expand its industrial scale.

Chengda Bio takes "providing high-quality biological products and protecting human life and health" as its corporate mission, always adhering to the core values of "integrity, benevolence, harmony, and cooperation", and the corporate philosophy of "facing life, only responsibility", and is committed to Become an international excellent biopharmaceutical company. In the near future, the company will continue to focus on the human vaccine industry, enrich and improve the vaccine product pipeline, and focus on the development of innovative vaccines such as recombinant protein vaccines, nucleic acid vaccines and polyvalent vaccines; in the medium and long term, the company will gradually extend to long-acting monoclonal antibody drugs, cells and gene therapy and other related business areas, and gradually build a biopharmaceutical industry cluster. In the future, the company will actively implement the national innovation and high-quality development strategy, put people's life and health in the first place, continue to adhere to the company's development strategy guided by clinical value, driven by technological innovation, and guaranteed by professionalism, and strictly control product quality And safety, continue to improve the social responsibility management system, and strive to contribute to the high-quality development of my country's biomedical industry.

Historical Evolution

Dedicatedly Offer Top-tier Biological Products, Wholeheartedly Safeguarding the Life and Health of Humanity

2002

1. CDBIO was officially registered and established in Shenyang City, on June 17th, 2002.
2. The technology platform was creatively introduced of high-density and suspension cell culture with micro-carrier in the bioreactor leading Chinese vaccine production technology into the international advanced ranks.
3. The factory was acquired to start the construction of manufacture facilities with the support of the design by experts of World Health Organization (WHO) and Food & Drug Administration, the United States (US FDA) and the high standard in Hunnan New District, Shenyang City.

2004

Rabies Vaccine for Human Use (Vero Cell) was approved by Sino Food & Drug Administration (SFDA, and with the current name of National Medical Product Administration, NMPA) in China.

2005

Rabies Vaccine for Human Use (Vero Cell) with Chinese brand of 成大速达® (Chengda Suda) was launched with the bioreactor manufacture process, and obtained the Certificate for the Release of Biological Products in China.

2006

1. Phase III clinical trial was finished of Inactivated Japanese Encephalitis Vaccine for Human Use (Vero Cell) developed and manufactured independently with advanced technology platform with the Chinese brand name of 成大利宝® (Chengda Libao).
2. CDBIO stepped into the inaugural Sales Boom Season with the sales revenue skyrocketing and exceeding 200 million yuan threshold.

2007

International business was started with Rabies Vaccine for Human Use (Vero Cell) initially registered in India, where it is the largest rabies vaccine market outside China.

2008

GMP certificate of NMPA was issued for Inactivated Japanese Encephalitis Vaccine for Human Use (Vero Cell) with the bioreactor manufacture process meaning IJEV was officially launched.

2009

1. Rabies Vaccine for Human Use (Vero Cell) seizes a market share of more than 50% firmly holding half of the human rabies vaccine market in China.
2. CDBIO has ascended to the top of Forbes' Chinese Most Promising Small and Medium-sized Enterprises List.

2010

It is approved for the production of Rabies Vaccine for Human Use (Vero Cell) with Zagreb 2-1-1 Regimen in China.

2011

Rabies Vaccine for Human Use (Vero Cell) has achieved a historic high in sales with the market share exceeding 70% and sales revenue surpassing 1 billion yuan.

2013

Beijing Cheng Da Tianhe Biotechnology Co., Ltd. (CDBIO (Tianhe)) was registered and founded in Beijing Economic-Technological Development Area (Beijing E-town) as one more new R&D center on December 16th, 2013.

2014

CDBIO was officially listed on the National Equities Exchange and Quotations (NEEQ with the stock No. of 831550) entering the capital market.

2017

PIC/S GMP certification was issued marking that quality management system of CDBIO was moving towards internationalization.

2019

Three major technical platforms were established including bacterial vaccine, viral vaccine and multi-combined & multivalent vaccine in order to improve the strategic blueprint of vaccine products.

2021

CDBIO was listed on the Science and Technology Innovation Board (SSE STAR Market) on October 28th, 2021.





Honors & Qualifications

Dedicatedly Offer Top-tier Biological Products, Wholeheartedly Safeguarding the Life and Health of Humanity